Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Column Group LLC

Q1 2024 · 13F-HR

Column Group LLCholdings as filed

Filed 2024-05-15 · accession 0000950123-24-005685

$160.5M
Reported value
7
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
87990A106TNYATenaya Therapeutics, Inc.$49.2M30.6%9,400,290CommonSOLE
68622P109ORICORIC Pharmaceuticals Inc.$48.7M30.3%3,540,777CommonSOLE
62921N105NGMUSDNGM Biopharmaceuticals Inc$28.8M18.0%18,136,735CommonSOLE
75382E109RAPT Therapeutics Inc$24.1M15.0%2,680,621CommonSOLE
86889P109Surrozen, Inc.$9.7M6.03%616,540CommonSOLE
786700104SGMTSagimet Biosciences Inc.$93,0560.06%17,169CommonSOLE
76155X100RVMDRevolution Medicines Inc$1,4830.00%46CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.